Research
Hormonal
Administration of Akkermansia muciniphila improves glucose metabolism and reduces fasting hyperglycemia in type 2 diabetic mouse models by decreasing gluconeogenesis.
Current research shows the bacterium Akkermansia muciniphila improves blood sugar control in diabetic mice, but it is not yet a confirmed or available probiotic treatment for humans.
ModerateSupportsMEDIUM confidence
A. muciniphila decreased glucose-6-phosphatase (G6pc) mRNA expression to counteract fasting hyperglycemia in the mouse model... Furthermore, administration of live A. muciniphila could also alleviate glucose intolerance.
Why this rating
Based on animal models (mice); human data is not yet established for this specific strain as a probiotic.
Source
Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics
Mingqian He et al. · Cell & Bioscience · 2017
DOI 10.1186/s13578-017-0183-1
narrative_reviewCited 328×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Administration of specific probiotic strains (e.g., Lactobacillus gasseri BNR17, L. acidophilus La5, Bifidobacterium lactis Bb12) and prebiotics (e.g., inulin-type fructans) reduces abdominal visceral fat, body weight, and fasting plasma glucose in overweight or obese individuals.Good
- Consumption of prebiotics (specifically inulin-type fructans) and probiotics reduces serum total and LDL cholesterol levels in hypercholesterolemic or dyslipidemic individuals.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →